BI 1265162

DRUG3 trials

Sponsors

Boehringer Ingelheim

Conditions

Cystic FibrosisHealthy

Phase 1

This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy Men

CompletedNCT03349723

Boehringer IngelheimHealthy

Start: 2017-11-23End: 2018-03-05Updated: 2022-04-11

This Study in Healthy Men Tests How Different Doses of BI 1265162 Are Taken up in the Body and How Well They Are Tolerated.

CompletedNCT03576144

Boehringer IngelheimHealthy

Start: 2018-07-11End: 2018-12-06Updated: 2022-02-23

Phase 2

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

TerminatedNCT04059094

Boehringer IngelheimCystic Fibrosis

Start: 2019-09-16End: 2020-04-24Updated: 2021-06-04

Related Papers

First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers

ERJ Open Research2020-12-109 citations

An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF<sup>TM</sup>1

ERJ Open Research2020-10-019 citations